Ospemifene: First Global Approval
Ospemifene: First Global Approval
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing AG
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing AG
Subjects
More information
Scope and Contents
Contents
Ospemifene (Osphena™) is an oral selective estrogen receptor modulator (SERM), with tissue-specific estrogenic agonist/antagonist effects. QuatRx Pharmaceuticals conducted the global development of the agent before licensing it to Shionogi for regulatory filing and commercialization worldwide. Ospemifene is the first non-estrogen treatment approved...
Alternative Titles
Full title
Ospemifene: First Global Approval
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1465556914
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1465556914
Other Identifiers
ISSN
0012-6667
E-ISSN
1179-1950
DOI
10.1007/s40265-013-0046-y
